THE PHARMACIST'S ROLE IN THE DRUGS AND THERAPEUTICS COMMITTEE (DTC)

OPPORTUNITETS AND PRIORITIES

DISCLOSURE

• Conflict of interest: nothing to disclose




AGENDA

- Introduction
- Drug and Therapeutics Committee (DTC)
- Drug formulary and formularymanagement
- Implementation



INTRODUCTION

- Hanne Plet, pharmacist (1991), PhD (2013)
- Hospital pharmacy since 1994
- Different roles as a pharmacist
- Member of the Drug and Therapeutics commitee (DTC) since 2000
- Building up the regional DTC in collaboration with clinical pharmacologist and hospitals
- Defining the role of the pharmacist in the DTC and in specialist groups
- PhD in developing and implementing hospital drug formulary




DRUGS AND THERAPEUT (CS

DEFINITION, GOAL/OBJECTIVES AND FUNCTIONS

DO DTCS HAVE A ROLE?

- People live longer get older
 More people have chronic diseases
 New (Expensive) (drug)treatments
 Expectations from the patients
 More people wishes health care services
- Limited amount of ressources



Hvis udviklingen fortsætter som nu, vil sundhedsudgifterne frem mod 2016 stige med 47 procent. Det svarer til en merudgift på 58 milliarder kroner i 2060. 14 procent skyldes, at der kommer flere ældre, 14 procent, at vi lever længere, og 19 procent at der hele tiden kommer nye og dyrere behandlingsformer til. **Developing treatment guidelines**

Developing and updating drug formulary

Performing formulary management

- Therapeutic interchange
- Use of patient's own drug
- Educational training of prescribers regarding drug cost
- Review of new therapeutic agents
- Approval of use of non-HDF drugs
- Non-HDF request form
- Regularly review of non-HDF
- Contacting physicians to change a non-HDF drug to a drug from the HDF

Developing drug use policy and guidelines

Performing drug use evaluation activities

Providing prescribers with objective information

- Newsletters
- Bulletins
- Results of drug use evaluation

THE MOST COMMON RESPONSIBILITIES AND ACTIVITIES OF THE DTCs

For more reading see WHO – Drug and Therapeutics Committee; a practical guide


http://apps.who.int /medicinedocs/en/d /Js4882e/

DTC – DECISION MAKING PROCESS

It depends on:

- The organisation of the DTC
- The functions of the DTC
- The responsibilities

The pharmacist has to present the medicine use problem considering patient, economy, safety and involving relevant people in the process.



*HTA – Health Technology assessment. See: http://www.who.int/medical_devices/assessment/en/

പ്പ D enmark 00 \square D 00

- Danish regions => responsible for health care
- Danish Medicines Council => developing national treatment guidelines
- National level Amgros => National tender for hospitals drugs and other

- Drug and therapeutics commitees
- Specialistgroups for treatment areas
- Regional drug formulary


Regional level

level

- Other groups eg. Policy and procedure for medication
- Implement the guidelines from the national council

- Adhere to the national and regional guideline
- Develop and adhere to standardassortment
- Follow guidelines for ordering drugs

EXERCISE - PHARMACIST'S ROLE - WHAT DO YOU PRIORITISE?



WHERE DO THE PHARMACIST'S HAVE A ROLE?

- Develope hospital drug formulary/treatment guidelines/therapeutic interchange
- Rational farmacotherapy (patient, economy, safety)
- Better patient safety
- Drug shortage
- Procurement
- Decision support in the CPOE Computer order entering
- Implementation of DTC decisions at the hospital
- Facilitate implementation at the hospital
- Monitor and follow up on medicine use
- Evaluate (do the doctors follow the guidelines/drug formulary?)
- Economy
 - Health Technology Assessment (HTA)
 - Medicine budget
- Better medicine processes (quality in workflows)




DRUG FORMULARYAND FORMULARY MANAGEMENT

PHARMACIST'S ROLE


DRUG FORMULARY - DEFINITION

A formulary is defined by WHO as a list containing essentiel drugs that are cost-effective, safe, available locally and of a quality that will satisfy the need of health care organizations and the patient.

WHY DO WE DEVELOPE A DRUG Formulary?



HOW DO WE CHOOSE THE DRUG TO Be used?



- Which specialities do the hospital have?
- What kind of diseases do you treat in each speciality?
- Do you have guidelines for therapeutic interchange?
- Do you have guideline for using patient's own drugs?
- What is the price of the drug?

DRUG USE AND THERAPEUTIC HIERARCHY

- NEW therapeutic princip REAL innovation
 - New mechanism of action
 - Better and/or more safe than the old treatment
 - Unmet medical need
- 'Me too' pseudo innovation
 - Terapeutic equivalent drugs
 - Biosimilars
 - New preparation (device etc.)
- Generica
- Obsolete drugs

willingness to pay

Country	Method	Description	
The Netherlands	System Objectified Judgment Analysis (SOJA) ((Janknegt R <i>et al.</i> 2007)	A model based on rational selection criteria such as clinical efficacy, adverse effects, dosage frequency, interactions, cost, and documentation. Besides rational selection criteria, other factors were included in decision-making such as emotional, personal financial and unconscious criteria.	EXAMPLES OF DRUG SELECTION METHODS
Northern Ireland	Safe Therapeutic Economic Pharmaceutical Selection (STEPS) (Scott M <i>et al.</i> 2007)	STEPS methodology was built on four steps. Step I: clinical evaluation (incorporating elements of SOJA), Step II: risk assessment, Step III: budgetary impact analysis, Step IV: final procurement selection.	When developing treatment guidelines and recommandation for drug formulary different methods exist.
USA	Formulary Leveraged Improved Prescribing (FLIP) (Schiff GD <i>et al.</i> , 2012)	A tool developed as part of a project at two US public academic hospitals consisting of a checklist of 48 questions for evaluating drugs requested for addition in the formulary. The questions were related to evidence of need, efficacy, medication, safety, misuse potential, cost issues, and decision-making processes.	However all methods do have a systematic aproach for choosing the "right" drug.
Denmark	GRADE approach (Grading of Recommendations Assessment, Development and Evaluation) http://www.gradeworkinggroup.o rg (www.medicinraadet.dk – English version exist)	 Formulating clinical questions and relevant PICO descriptions Systematic literature search Selecting literature Assessment of the risk of bias Summary of results Assessment of confidence in the estimates Development of guideline recommendations 	

DRUG FORMULARIES AT DIFFERENT LEVELS

Drug formulary	Developed by
National drug formulary	Based on guidelines from the Medicin Council (No list exist – however the formulary can be found for each diseasearea) The pharmacist should be represented
Regional hospital drug formulary	DTC responsible Specialist groups including pharmacist's The pharmacist should be represented
Ward list	The ward (managing doctor at the ward) develop the list together with the pharmacist

Formulary management

Or perhaps this is the real world se,

Drug Management Cycle Policy AN' Selection 7 Customs QUESTIC Dosage d Chain Mat Stock stance Management Availability Storage Prescript Practices - Budget

DRUG SHORTAGE

Considerations (model from Hospital Pharmacy North Denmark region):

- Generics in other strengths, package, device etc.
- Therapeutic equivalent drug (PPI, LMWH, etc.)
- Drugs not markedet in fx Denmark but in another country
- Extemporaneous drug (preparation of a drug to a specific patient (or situation))

INVOLVE THE DTC IF NECESSARY



Medicines shortages in European hospitals

 99% of hospital pharmacists report experiencing problems with medicines shortages in the past year

 63% of hospital pharmacists report that medicines shortages are a weekly, sometimes daily, occurrence

• 77% of hospital pharmacists report that medicines shortages have became worse over the past year


Survey by the European Association of Hospital Pharmacists on medicines shortages, September 2012-February 2013



IMPLEMENTATION MONITORING EVALUATION

PHARMACIST'S ROLE

Figure 2. The coordinated implementation model (77).



Source: Lomas J. et. al. 1993 Diffusion, dissemination, and implementation: who should do what?

IMPLEMENTATION

Multifacetted interventions are needed

Different kind of information combined with dialoque, written material and drug-use evaluation (multifacetted intervention) has the biggest impact on implementation.


Economic incentives => money always has an effect

Inspiration from the pharmaceutical industry:

- □ Academic detailing (face to face visit)
- Group detailing

Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004 Feb;8(6):iii-72.

NATIONAL GUIDELINES – REGIONAL Proces for implementation



IMPLEMENTATION AND TYPE OF Switch between drugs

- Simple switch between drugs =>
 - A list is published at the home page then it is made automatically
- Drug switch with high complexity =>
 - Example change in:
 - Strenght
 - Device
 - Another way the drug is going to be handled
 - More information/dialogue with the physician and nurse



NON-ADHERENT TO THE GUIDELINES/FORMULARIES



- Explanatory variables:
 - Patient did not come to the appointment
 - No new patient included
 - Small patientpopulation
- Resistance against change?
- What can the pharmacist do?

EXAMPLE - IMPLEMENTATION OF GROWTH HORMON

- New national treatment guideline and drug recommandation
- Problems
 - "Biosimilar"; many users; treatment at home;
- Meetings with the wards Children AAUH og Vendsyssel samt Endokrinology (adults).
- Meeting with company (I. choice) and wards
- Development of written information to the patient
- Monitoring the use of growth hormon
- Dialoque if non-adherent with the guideline
- Goal:
 - 80 % I. choice to adults
 - 50 % I. choice to children




EXAMPLE – GROWTH HORMONE Impact of the effort

Figur 27. Procentvis fordeling ift. mængde (DDD) for væksthormoner for de forbrugende afdelinger.




Figur 25. Totalforbrug opgjort i mængde (DDD) og beløb (kr.) for væksthomoner.



Endokrinologisk

EXAMPLE – DEVELOPING A TOOL TO PRESCRIBE "PAINKILLERS"

- High use of oxycodon in primary care and hospitals (Morphin is I. choice)
- Morphine should be used as 1st choice
- Many wards involved
- Many opinion leaders
- Reduce the amount of opioids used in North Denmark Region
- A group from primary care and hospitals developed a small guideline to help the phycisian's to prescribe "pain-killers"
- Printed and distributed to all the physicians in the region
- https://www.sundhed.dk/content/cms/97/14797_smertemanual--version-2_2013.pdf



THANK YOU FOR LISTENING

HANNE TOVERUD PLET PHD, CLINICAL PHARMACIST HOSPITAL PHARMACY OF NORTH DENMARK REGION MAIL: <u>HTP@RN.DK</u> PHONE: +45 3060 0939

TAKE HOME MESSAGES

- Pharmacist's role in Drug & Therapeutics committee depends on: the organisation; the medicine problem in your organisation; how "old" the DTC is (years of existence) and ressources
- Write down the problems related to medicine use in your organisation. Prioritise the
 problems which have the largest impact on patient safety, clinical outcome and
 health/pharmacoeconomy. Focus on the problems with the largest impact and present
 them for the DTC.
- Show the effect of the activities by using data. Focus on few problems and show that the pharmacist makes a difference and present it for the DTC

